GlassScriptPhysician profile
Michael P Volpe
NPI 1407875701
$13,934.02
in general payments reported to CMS, 2019-2025
42 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,485 · 2020: $890 · 2021: $2,183 · 2022: $2,644 · 2023: $2,540 · 2024: $2,362 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,712 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,712.36 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,392.60 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,652.80 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,376.78 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,332.56 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $1,009.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $970.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $613.34 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $506.39 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.67 | 2019-2025 | Jardiance |
| Pfizer INC. | $365.88 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.44 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $285.20 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $242.01 | 2021-2025 | Veozah |
| Alnylam Pharmaceuticals INC. | $214.45 | 2020-2024 | Onpattro |
| Axsome Therapeutics, INC. | $197.11 | 2023-2025 | Auvelity |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Volpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.